research [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats].
Testosterone undecanoate can reduce the negative effects of Finasteride on male reproductive health.
Search
for
Sort by
Research
510-540 / 1000+ resultsresearch 胃切除・腸切除術後の退院指導-パンフレットを使用して-
Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
research Evidence for the off-label use of tofacitinib in alopecia areata
Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Regarding prostate-specific antigen: let's not shoot the messenger
The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
research 5α‐Reductase inhibitors and prostatic disease
5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)
Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period
Using finasteride with TIP extends time off period for prostate cancer patients.
research 448 Challenges of securing insurance approval for oral tofacitinib treatment of alopecia areata: A multi-institutional retrospective review
Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
research Plant responses to shade
Plants change their growth in response to shade based on light signals detected by phytochrome.
research Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
research Alopecia universalis successfully treated with tofacitinib
Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
research Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5α-reductase inhibitor
Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
research PROTECTIVE EFFECT OF TRIBULUS TERRESTRIS ON HEPATO-BIOCHEMICAL PARAMETERS OF ALBINO RAT AFTER TREATMENT WITH DRUG CYPROTERONE ACETATE
Tribulus terrestris may protect the liver from drug damage.
research The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific
Dutasteride and finasteride affect different cell types differently.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
research Un nuevo anovulador antiandrogénico
El acetato de ciproterona trata problemas androgénicos como hirsutismo, acné, seborrea y alopecia con diferentes dosis y combinaciones.
research Aim to alleviate alopecia areata with newly available agents
New treatments like JAK inhibitors offer hope for better alopecia areata management.
research A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
research Raltegravir-Induced Alopecia in an HIV+ Patient
Raltegravir may cause hair loss in some patients.
research Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
research Intraoperative Floppy Iris Syndrome: Updated Perspectives
Identifying and managing risk factors before cataract surgery is crucial to prevent complications.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles.
CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.